<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE- carisoprodol, aspirin and codeine phosphate tablet </strong><br>Eon Labs, Inc.<br></p></div>
<h1>
<span class="Bold">Carisoprodol</span><span class="Bold">, Aspirin and Codeine Phosphate Tablets, </span><span class="Bold">USP  CIII</span><span class="Bold">             Rx only<br> WARNING:  May be habit-forming</span>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="ID_909f6480-89fd-4954-a6ac-ec0162a2973b"></a><a name="section-1"></a><p></p>
<h1>WARNING: <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> Related to Ultra-Rapid Metabolism of Codeine to Morphine</h1>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have occurred in children who received codeine following tonsillectomy and/or adenoidectomy and had evidence of being ultra-rapid metabolizers of codeine due to CYP2D6 polymorphism (see <a href="#i4i_warnings_id_e0327034-1ad9-4382-9266-207bd2368459">WARNINGS</a> – <a href="#i4i_section_id_7f8f16b7-a515-4371-8d83-820dadac35e8">Codeine Phosphate</a>-<a href="#i4i_section_id_7f8f16b7-a515-4371-8d83-820dadac35e8"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> Related to Ultra-Rapid Metabolism of Codeine to Morphine</a>).</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_c2f0eb08-60fe-4764-8f9b-028e5b71b5a1"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Carisoprodol, Aspirin and Codeine Phosphate Tablets, USP is a fixed-dose combination product containing the following three products:</p>
<dl>
<dt>•</dt>
<dd>200 mg of carisoprodol, a centrally-acting muscle relaxant</dd>
<dt>•</dt>
<dd>325 mg of aspirin, an analgesic with antipyretic and anti-inflammatory properties.</dd>
<dt>•</dt>
<dd>16 mg of codeine phosphate, a centrally-acting narcotic analgesic.</dd>
</dl>
<p>It is available as a round, two-layered yellow and white tablet for oral administration.</p>
<p><span class="Bold"><span class="Italics">Carisoprodol</span></span><span class="Bold"><span class="Italics">: </span></span>Chemically, carisoprodol is <span class="Italics">N</span>-isopropyl-2-methyl-2-propyl-1,3-propanediol dicarbamate and its molecular formula is C<span class="Sub">12</span>H<span class="Sub">24</span>N<span class="Sub">2</span>O<span class="Sub">4</span>, with a molecular weight of 260.34. The structural formula of carisoprodol is:</p>
<div class="Figure">
<a name="id300"></a><img alt="Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dcae7a8a-9d9e-4f7f-954c-39e371f30f75&amp;name=a6b304e5-073f-48b6-9f17-ddfa94ecf2db-01.jpg">
</div>
<p><span class="Bold"><span class="Italics">Aspirin: </span></span>Chemically, aspirin (acetylsalicyclic acid) is 2-(acetyloxy)-, benzoic acid and its molecular formula is C<span class="Sub">9</span>H<span class="Sub">8</span>O<span class="Sub">4</span>, with a molecular weight of 180.16. The structural formula of aspirin is:</p>
<div class="Figure">
<a name="id309"></a><img alt="structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dcae7a8a-9d9e-4f7f-954c-39e371f30f75&amp;name=a6b304e5-073f-48b6-9f17-ddfa94ecf2db-02.jpg">
</div>
<p><span class="Italics"><span class="Bold">Codeine Phosphate</span>: </span>Chemically, codeine phosphate is 7,8-Didehydro-4,5α-epoxy-3-methoxy-17-methylmorphinan-6α-ol phosphate (1:1) (salt) hemihydrate and its molecular formula is C<span class="Sub">18</span>H<span class="Sub">24</span>NO<span class="Sub">7</span>P, with a molecular weight of 406.37. The structural formula of codeine phosphate is:</p>
<div class="Figure">
<a name="id315"></a><img alt="structure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dcae7a8a-9d9e-4f7f-954c-39e371f30f75&amp;name=a6b304e5-073f-48b6-9f17-ddfa94ecf2db-03.jpg">
</div>
<p>Each tablet, for oral administration, contains carisoprodol 200 mg, aspirin 325 mg, and codeine phosphate 16 mg. In addition, each tablet contains the following inactive ingredients: colloidal silicon dioxide, corn starch, croscarmellose sodium, D&amp;C Yellow No. 10 Aluminum Lake, magnesium stearate, microcrystalline cellulose, povidone and stearic acid. </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_f9ac66b6-70f4-4143-895c-20a30b3b5200"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2609c48a-73ea-49a7-9758-f1fc21c2fab7"></a><a name="section-2.1"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First"><span class="Bold"><span class="Italics">Carisoprodol</span></span><span class="Bold"><span class="Italics"></span></span></p>
<p>The mechanism of action of carisoprodol in relieving <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> associated with acute painful musculoskeletal conditions has not been clearly identified. In animal studies, <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">muscle relaxation</span> induced by carisoprodol is associated with altered interneuronal activity in the spinal cord and in the descending reticular formation of the brain.</p>
<p><span class="Bold"><span class="Italics">Aspirin</span></span></p>
<p>The mechanism of action of aspirin in relieving <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> is by inhibition of the body's production of prostaglandins, which are thought to cause <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> sensations by stimulating muscle contractions and dilating blood vessels.</p>
<p><span class="Bold"><span class="Italics">Codeine Phosphate</span></span></p>
<p>The precise mechanism of action of codeine phosphate, an opioid agonist, in relieving <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> has not been established. The binding of codeine phosphate to mu, delta, and kappa opioid receptors in the central nervous system (CNS) may change the perception of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. The analgesic activity of codeine phosphate is probably due to its conversion to morphine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c52b4401-b9e7-4e46-ab76-31c753e7c322"></a><a name="section-2.2"></a><p></p>
<h2>Pharmacodynamics</h2>
<p class="First"><span class="Bold"><span class="Italics">Carisoprodol</span></span><span class="Bold"><span class="Italics"></span></span></p>
<p>Carisoprodol is a centrally-acting muscle relaxant that does not directly relax <span class="product-label-link" type="condition" conceptid="4136244" conceptname="Feeling tense">tense</span> skeletal muscles. A metabolite of carisoprodol, meprobamate, has anxiolytic and sedative properties. The degree to which these properties of meprobamate contribute to the safety and efficacy of Carisoprodol, Aspirin and Codeine Phosphate Tablets is unknown.</p>
<p><span class="Bold"><span class="Italics">Aspirin </span></span></p>
<p>Aspirin is a non-narcotic analgesic with anti-inflammatory and anti-pyretic activity. Inhibition of prostaglandin biosynthesis appears to account for most of its anti-inflammatory and for at least part of its analgesic and antipyretic properties. In the CNS, aspirin works on the hypothalamus heat-regulating center to reduce <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. Aspirin can cause serious <span class="product-label-link" type="condition" conceptid="4168618" conceptname="Injury of gastrointestinal tract">gastrointestinal injury</span> including <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, obstruction, and perforations from <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> possibly by inhibition of the production of prostaglandins, compromising the defenses of the gastric mucosa and the activity of substances involved in tissue repair and <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> healing (see <span class="Bold"><a href="#i4i_warnings_id_e0327034-1ad9-4382-9266-207bd2368459">WARNINGS</a></span>).<span class="Bold"></span>Aspirin inhibits platelet aggregation by irreversibly inhibiting prostaglandin cyclo-oxygenase. This effect lasts for the life of the platelet and prevents the formation of the platelet aggregating factor thromboxane A2.</p>
<p><span class="Bold"><span class="Italics">Codeine Phosphate </span></span></p>
<p>Codeine phosphate is a centrally-acting narcotic analgesic. Its actions are qualitatively similar to morphine, but its potency is substantially less. Opioids, including codeine phosphate have the following effects:</p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> by a direct effect on the brainstem respiratory centers</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of the <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> reflex by direct effect on the <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> center in the medulla</dd>
<dt>•</dt>
<dd>constriction of the pupils (i.e., <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>)</dd>
<dt>•</dt>
<dd>decreased gastric, biliary, and pancreatic secretions</dd>
<dt>•</dt>
<dd>reduction in the motility of the stomach and small and large intestine which results in <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> and delayed digestion</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> by directly stimulating the chemoreceptor trigger zone</dd>
<dt>•</dt>
<dd>increased biliary tract pressure as a result of spasm of the sphincter of Oddi</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">peripheral vasodilatation</span> which may result in <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span></dd>
<dt>•</dt>
<dd>histamine release which may result in <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, and <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span></dd>
<dt>•</dt>
<dd>increased tone of the bladder detrusor muscle, ureters, and vesical sphincter which may result in <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span></dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c15e7b83-6d4f-48af-95cf-6323aa6cc095"></a><a name="section-2.3"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First"><span class="Bold"><span class="Italics">Carisoprodol</span></span><span class="Bold"><span class="Italics"></span></span></p>
<p>The pharmacokinetics of carisoprodol and its metabolite meprobamate were studied in a study of 24 healthy subjects (12 male and 12 female) who received single doses of 350 mg of carisoprodol (see <span class="Bold">Table 1</span>). The C<span class="Sub">max</span> of meprobamate was 2.5 ± 0.5 mcg/mL (mean ± SD) after administration of a single 350 mg dose of carisoprodol, which is approximately 30% of the C<span class="Sub">max</span> of meprobamate (approximately 8 mcg/mL) after administration of a single 400 mg dose of meprobamate.</p>
<p><span class="Bold">Table 1.</span><span class="Bold"> Pharmacokinetic Parameters of </span><span class="Bold">Carisoprodol</span><span class="Bold"> and </span><span class="Bold">Meprobamate</span><span class="Bold"> (Mean </span>± <span class="Bold">SD, n=24)</span></p>
<table>
<col width="24%">
<col width="24%">
<col width="24%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule"></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First"><span class="Bold">Carisoprodol</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Meprobamate</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">C<span class="Sub">max</span> (mcg/mL)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">1.8 ± 1</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2.5 ± 0.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">AUC<span class="Sub">inf</span> (mcg·hour/mL)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">7 ± 5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">46 ± 9</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">T<span class="Sub">max</span> (hour)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">1.7 ± 0.8</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">4.5 ± 1.9</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First">T<span class="Sub">1/2</span> (hour)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">2 ± 0.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">9.6 ± 1.5</p></td>
</tr>
</tbody>
</table>
<p><span class="Italics">Absorption: </span>Absolute bioavailability of carisoprodol has not been determined. After administration of a single dose of 350 mg of carisoprodol, the mean time to peak plasma concentrations (T<span class="Sub">max</span>) of carisoprodol was approximately 1.5 to 2 hours. Co-administration of a high-fat meal with 350 mg of carisoprodol had no effect on the pharmacokinetics of carisoprodol.</p>
<p><span class="Italics">Metabolism: </span>The major pathway of carisoprodol metabolism is via the liver by cytochrome enzyme CYP2C19 to form meprobamate. This enzyme exhibits genetic polymorphism (see Patients with Reduced CYP2C19 Activity below).</p>
<p><span class="Italics">Elimination: </span>Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours after administration of a single dose of 350 mg of carisoprodol. The half-life of meprobamate is approximately 10 hours after administration of a single dose of 350 mg of carisoprodol.</p>
<p><span class="Italics">Gender: </span>Exposure of carisoprodol is higher in females than in male subjects (approximately 30 to 50% on a weight adjusted basis). Overall exposure of meprobamate is comparable between female and male subjects.</p>
<p><span class="Italics">Patients with Reduced CYP2C19 Activity: </span>Carisoprodol should be used with caution in patients with reduced CYP2C19 activity. Published studies indicate that patients who are poor CYP2C19 metabolizers have a 4-fold increase in exposure to carisoprodol, and 50% reduced exposure to meprobamate compared to normal CYP2C19 metabolizers. The prevalence of poor metabolizers in Caucasians and African Americans is approximately 3 to 5% and in Asians is approximately 15 to 20%.</p>
<p><span class="Bold"><span class="Italics">Aspirin</span></span></p>
<p><span class="Italics">Absorption:  </span>The rate of aspirin absorption from the gastrointestinal (GI) tract is dependent upon the presence or absence of food, gastric pH (the presence or absence of GI antacids), and other physiologic factors. Following absorption, aspirin is hydrolyzed to salicylic acid in the gut wall and during first-pass metabolism with peak plasma levels of salicylic acid occurring within 1 to 2 hours of dosing.</p>
<p><span class="Italics">Distribution: </span>Salicylic acid is widely distributed to all tissues and fluids in the body including the central nervous system (CNS), breast milk, and fetal tissues. The highest concentrations are found in the plasma, liver, kidneys, heart, and lungs. The protein binding of salicylate is concentration dependent, i.e., nonlinear. At plasma concentrations of salicylic acid, &lt; 100 mcg/mL and &gt; 400 mcg/mL, approximately 90 and 76 percent of plasma salicylate is bound to albumin, respectively.</p>
<p><span class="Italics">Metabolism: </span>Aspirin, which has a half-life of about 15 minutes, is hydrolyzed in the plasma to salicylic acid such that plasma levels of aspirin may not be detectable 1 to 2 hours after dosing. Salicylic acid, which has a plasma half-life of approximately 6 hours, is conjugated in the liver to form salicyluric acid, salicyl phenolic glucuronide, salicyl acyl glucuronide, gentisic acid, and gentisuric acid. At higher serum concentrations of salicylic acid, the total clearance of salicylic acid decreases due to the limited ability of the liver to form both salicyluric acid and phenolic glucuronide. Following toxic doses of aspirin (e.g., &gt; 10 grams), the plasma half-life of salicylic acid may be increased to over 20 hours.</p>
<p><span class="Italics">Elimination: </span>The elimination of salicylic acid is constant in relation to the plasma salicylic acid concentration. Following therapeutic doses of aspirin, approximately 75, 10, 10, and 5 percent is found excreted in the urine as salicyluric acid, salicylic acid, a phenolic glucuronide of salicylic acid, and an acyl glucuronide of salicylic acid, respectively. As the urinary pH rises above 6.5, the renal clearance of free salicylate increases from less than 5 percent to greater than 80 percent. Alkalinization of the urine is a key concept in the management of salicylate <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> (see <span class="Bold"><a href="#i4i_overdosage_id_f4be16ec-411d-4db0-baf0-1ff24888d9b9">OVERDOSAGE</a>, Treatment of </span><span class="Bold">Overdosage</span>).<span class="Bold"></span>Clearance of salicylic acid is also reduced in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
<p><span class="Bold"><span class="Italics">Codeine Phosphate</span></span></p>
<p><span class="Italics">Absorption: </span>Codeine is readily absorbed from the GI tract. At therapeutic doses, the <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span> reaches a peak within 2 hours and persists between 4 and 6 hours.</p>
<p><span class="Italics">Distribution: </span>Codeine is rapidly distributed from the intravascular spaces to the tissues with preferential uptake by the liver, spleen, and kidney. Codeine crosses the blood-brain barrier, and is found in fetal tissue and breast milk. The plasma concentration of codeine does not correlate with brain concentration of codeine or the relief of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</p>
<p><span class="Italics">Metabolism: </span>The plasma half-life of codeine is about 2.9 hours.</p>
<p><span class="Italics">Elimination: </span>The elimination of codeine is primarily via the kidneys, and about 90% of an oral dose is excreted by the kidneys within 24 hours of dosing. The urinary secretion products consist of free and glucuronide-conjugated codeine (about 70%), free and conjugated norcodeine (about 10%), free and conjugated morphine (about 10%), normorphine (4%), and hydrocodone (1%). The remainder of the dose is excreted in the feces.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_c7bad52d-88b9-4fca-a464-fef1aa20adf7"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Carisoprodol, Aspirin and Codeine Phosphate Tablets, USP are indicated for the relief of <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> associated with acute, painful musculoskeletal conditions in adults. Carisoprodol, Aspirin and Codeine Phosphate Tablets, USP should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration (see <span class="Bold"><a href="#i4i_dosage_admin_id_f4c8befc-3509-4f13-9561-de990cf84bcb">DOSAGE AND ADMINISTRATION</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_00b7e679-a17f-4e20-82f9-fe14d1091a97"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Carisoprodol, Aspirin and Codeine Phosphate Tablets are contraindicated in patients with a history of:</p>
<dl>
<dt>•</dt>
<dd>a serious GI complication (i.e., <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, perforations, obstruction) due to aspirin use</dd>
<dt>•</dt>
<dd>aspirin induced <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> (a symptom complex which occurs in patients who have <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, rhinosinusitis, and <span class="product-label-link" type="condition" conceptid="253788" conceptname="Nasal polyp">nasal polyps</span> who develop a severe, potentially fatal <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> shortly after taking aspirin or other NSAIDs)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to a carbamate such as meprobamate</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4120604" conceptname="Acute intermittent porphyria">acute intermittent porphyria</span></dd>
<dt>•</dt>
<dd>Codeine sulphate is contraindicated for <span class="product-label-link" type="condition" conceptid="439502" conceptname="Postoperative pain">postoperative pain</span> management in children who have undergone tonsillectomy and/or adenoidectomy (see <span class="Bold"><a href="#i4i_warnings_id_e0327034-1ad9-4382-9266-207bd2368459">WARNINGS</a> – <a href="#i4i_section_id_7f8f16b7-a515-4371-8d83-820dadac35e8">Codeine Phosphate</a> – <a href="#i4i_section_id_7f8f16b7-a515-4371-8d83-820dadac35e8"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> Related to Ultra-Rapid Metabolism of Codeine to Morphine</a></span>).</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_e0327034-1ad9-4382-9266-207bd2368459"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_58b4b38a-fab2-427c-a2f2-925ac6437ef4"></a><a name="section-5.1"></a><p></p>
<h2>Carisoprodol</h2>
<p class="First"><span class="Bold"><span class="Italics">Sedation</span></span></p>
<p>Carisoprodol has sedative properties and may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a motor vehicle or operating machinery. There have been post-marketing reports of <span class="product-label-link" type="condition" conceptid="435134" conceptname="Motor vehicle accident">motor vehicle accidents</span> associated with the use of carisoprodol.</p>
<p>Since the sedative effects of carisoprodol and other CNS depressants (e.g., alcohol, benzodiazepines, opioids, tricyclic antidepressants) may be additive, appropriate caution should be exercised with patients who take more than one of these CNS depressants simultaneously.</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug Dependence</span>, Withdrawal, and Abuse</span></span></p>
<p>Carisoprodol, the active ingredient, has been subject to abuse, <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, withdrawal, misuse, and criminal diversion (see <span class="Bold"><a href="#i4i_abuse_dependence_id_ba20f581-ba78-4354-8ba1-6db7390d3e66">DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a></span>). Abuse of Carisoprodol poses a risk of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> which may lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, CNS and <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> and other disorders (see <span class="Bold"><a href="#i4i_overdosage_id_f4be16ec-411d-4db0-baf0-1ff24888d9b9">OVERDOSAGE</a></span>).</p>
<p>Post-marketing cases of carisoprodol abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> have been reported in patients with prolonged use and a history of drug abuse. Although most of these patients took other drugs of abuse, some patients solely abused carisoprodol. Withdrawal symptoms have been reported following abrupt cessation of carisoprodol after prolonged use. Reported withdrawal symptoms included <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">muscle twitching</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, and <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>.  One of carisoprodol’s metabolites, meprobamate, (a controlled substance), may also cause <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> (see <span class="Bold"><a href="#i4i_clinical_pharmacology_id_f9ac66b6-70f4-4143-895c-20a30b3b5200">CLINICAL PHARMACOLOGY</a></span>).</p>
<p>To reduce the risk of carisoprodol abuse, assess the risk of abuse prior to prescribing.  After prescribing, limit the length of treatment to three weeks for the relief of acute musculoskeletal <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, keep careful prescription records, monitor for signs of abuse and <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, and educate patients and their families about abuse and on proper storage and disposal.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_16ddedab-3460-4edb-a5c2-96e9ceaaf24a"></a><a name="section-5.2"></a><p></p>
<h2>Aspirin</h2>
<p class="First"><span class="Bold"><span class="Italics">Serious Gastrointestinal Adverse Reactions</span></span></p>
<p>Aspirin can cause serious gastrointestinal (GI) adverse reactions including <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, perforation, and obstruction of the stomach, small intestine, or large intestine, which can be fatal. Aspirin-associated serious GI adverse reactions can occur anywhere along the GI tract, at any time, with or without warning symptoms. Patients at higher risk of aspirin-associated serious upper GI adverse reactions include patients with a history of aspirin-associated GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> from <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> (complicated <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span>), a history of aspirin-associated <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> (uncomplicated <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span>), geriatric patients, patients with poor baseline health status, patients taking higher doses of aspirin, and patients taking concomitant anticoagulants, NSAIDs, and/or large amounts of alcohol. To minimize the risk for aspirin-associated GI serious adverse reactions, the lowest effective aspirin dose should be used for the shortest possible duration.</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> and </span></span><span class="Bold"><span class="Italics">Anaphylactoid</span></span><span class="Bold"><span class="Italics"> Reactions</span></span></p>
<p>Aspirin may cause an increased risk of serious <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>, which can occur in patients without known prior exposure to aspirin (see <span class="Bold"><a href="#i4i_contraindications_id_00b7e679-a17f-4e20-82f9-fe14d1091a97">CONTRAINDICATIONS</a></span>).<span class="Bold"></span>Patients with a serious <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span> should receive emergency care.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7f8f16b7-a515-4371-8d83-820dadac35e8"></a><a name="section-5.3"></a><p></p>
<h2>Codeine Phosphate</h2>
<p class="First"><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> Related to Ultra-Rapid Metabolism of Codeine to Morphine</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have occurred in children who received codeine in the post-operative period following tonsillectomy and/or adenoidectomy and had evidence of being ultra-rapid metabolizers of codeine (i.e., multiple copies of the gene for cytochrome P450 isoenzyme 2D6 [CYP2D6] or high morphine concentrations). <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> have also occurred in nursing infants who were exposed to high levels of morphine in breast milk because their mothers were ultra-rapid metabolizers of codeine (see <span class="Bold"><a href="#i4i_precautions_id_4e64cc3d-ad51-4846-a3c9-7cf3a20347fb">PRECAUTIONS</a> – <a href="#i4i_nursing_mothers_id_bad4488a-e24d-4cf8-b3d0-338349a7b066">Nursing Mothers</a></span>).</p>
<p>Some individuals may be ultra-rapid metabolizers because of a specific CYP2D6 genotype (gene duplications denoted as *1/*1xN or *1/*2xN). The prevalence of this CYP2D6 phenotype varies widely and has been estimated at 0.5 to 1% in Chinese and Japanese, 0.5 to 1% Hispanics, 1 to 10% in Caucasians, 3% in African Americans, and 16 to 28% in North Africans, Ethiopians, and Arabs. Data are not available for other ethnic groups. These individuals convert codeine into its active metabolite, morphine, more rapidly and completely than other people. This rapid conversion results in higher than expected serum morphine levels. Even at labeled dosage regimens, individuals who are ultra-rapid metabolizers may have life-threatening or fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> or experience signs of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> (such as extreme <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, or <span class="product-label-link" type="condition" conceptid="4302536" conceptname="Shallow breathing">shallow breathing</span>) (see <span class="Bold"><a href="#i4i_overdosage_id_f4be16ec-411d-4db0-baf0-1ff24888d9b9">OVERDOSAGE</a></span>).</p>
<p>Children with obstructive <span class="product-label-link" type="condition" conceptid="313459" conceptname="Sleep apnea">sleep apnea</span> who are treated with codeine for post-tonsillectomy and/or adenoidectomy <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> may be particularly sensitive to the respiratory depressant effects of codeine that has been rapidly metabolized to morphine. Codeine is contraindicated for post-operative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> management in all pediatric patients undergoing tonsillectomy and/or adenoidectomy (see <span class="Bold"><a href="#i4i_contraindications_id_00b7e679-a17f-4e20-82f9-fe14d1091a97">CONTRAINDICATIONS</a></span>).</p>
<p>When prescribing codeine-containing drug, healthcare providers should choose the lowest effective dose for the shortest period of time and inform patients and caregivers about these risks and the signs of morphine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> (see <span class="Bold"><a href="#i4i_overdosage_id_f4be16ec-411d-4db0-baf0-1ff24888d9b9">OVERDOSAGE</a></span>).</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></span></span></p>
<p><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> is a serious adverse reaction of opioid agonists, including codeine phosphate. Opioid-associated <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> is more likely to occur in geriatric patients, debilitated patients, in non-tolerant patients who are given large initial doses of opioids, and in patients who are receiving concomitant respiratory depressants (e.g. other opioids, benzodiazepines, tricyclic antidepressants, phenothiazines, skeletal muscle relaxants, alcohol). In addition, patients with <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> (<span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>), restrictive <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span>, decreased respiratory drive, and/or <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> are at a greater risk of opioid-associated <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. Opioid-associated <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> may be increased in patients with <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span> (e.g., patients with head <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, intracranial lesions).</p>
<p><span class="Bold"><span class="Italics">Abuse and Diversion</span></span></p>
<p>Codeine phosphate is a Schedule III controlled substance. Administration of opioids including codeine phosphate has been associated with abuse. Healthcare professionals should contact their State Professional Licensing Board or State Substances Authority for information on how to prevent or detect abuse or diversion of codeine phosphate.</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span> and Tolerance</span></span></p>
<p>Use of opioids, including codeine phosphate, can result in psychological and/or physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>. Withdrawal symptoms associated with abrupt opioid discontinuation include <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">tachypnea</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, and/or <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. The use of opioids, including codeine phosphate, use can result in tolerance - the need for increasing doses to maintain a desired effect in the absence of other factors (e.g., disease progression).</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4129389" conceptname="Gastrointestinal obstruction">Gastrointestinal Obstruction</span></span></span></p>
<p>Opioids, including codeine phosphate, may cause <span class="product-label-link" type="condition" conceptid="4129389" conceptname="Gastrointestinal obstruction">gastrointestinal obstruction</span>.</p>
<p><span class="Bold"><span class="Italics">Sedation</span></span></p>
<p>Opioids, including codeine phosphate, may impair the mental and physical abilities required for the performance of potentially hazardous tasks such as driving a motor vehicle or operating machinery. Since the sedative effects of codeine phosphate and other CNS depressants (e.g., other opioids, benzodiazepines, tricyclic antidepressants, skeletal muscle relaxants, alcohol) may be additive, appropriate caution should be exercised with patients who take more than one of these CNS depressants simultaneously.</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></span></span></p>
<p>The use of opioids, including codeine phosphate, may cause <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. Opioid-associated <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> is more likely in patients with <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> or with the concomitant use of drugs associated with <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_4e64cc3d-ad51-4846-a3c9-7cf3a20347fb"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5e5b27d7-06a8-4252-b971-02aeb8435eb4"></a><a name="section-6.1"></a><p></p>
<h2>Patients with impaired renal or hepatic function</h2>
<p class="First">The safety and pharmacokinetics of Carisoprodol, Aspirin and Codeine Phosphate Tablets in patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> have not been evaluated.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_53c92b4e-3ec2-479e-9822-2df8c7ae865f"></a><a name="section-6.1.1"></a><p></p>
<h3>Carisoprodol</h3>
<p class="First">Since carisoprodol is excreted by the kidney and is metabolized in the liver, caution should be exercised if carisoprodol is administered to patients with impaired renal or hepatic function. Carisoprodol is dialyzable by hemodialysis and peritoneal dialysis.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></span></p>
<p>There have been post-marketing reports of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in patients who received carisoprodol. Most of these cases have occurred in the setting of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">multiple drug overdoses</span> (including drugs of abuse, illegal drugs, and alcohol) (see <span class="Bold"><a href="#i4i_overdosage_id_f4be16ec-411d-4db0-baf0-1ff24888d9b9">OVERDOSAGE</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ced5dad2-a8ae-43bf-b90f-2e9aa1d5d29b"></a><a name="section-6.1.2"></a><p></p>
<h3>Aspirin</h3>
<p class="First"><span class="Italics">Gastrointestinal Adverse Reactions</span></p>
<p>In addition to serious gastrointestinal adverse reactions, the use of aspirin is also associated with <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, gastrointestinal erosions, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (see <span class="Bold"><a href="#i4i_warnings_id_e0327034-1ad9-4382-9266-207bd2368459">WARNINGS</a>, <a href="#i4i_warnings_id_e0327034-1ad9-4382-9266-207bd2368459">Serious Gastrointestinal Adverse Reactions</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0f86402b-82ac-4253-bdf5-a68d638de334"></a><a name="section-6.1.3"></a><p></p>
<h3>Codeine Phosphate</h3>
<p class="First"><span class="Italics">Obscuring Medical Conditions</span></p>
<p>Opioids, including codeine phosphate, may obscure the clinical course of patients with head injuries because of the CNS depressive effects of opioids. In addition, opioids, including codeine phosphate, may obscure the symptoms and/or signs that are used for the diagnosis or for the monitoring of patients with acute abdominal conditions.</p>
<p><span class="Italics">Use in Patients with Pancreatic or Biliary Duct Disease</span></p>
<p>Opioids, including codeine phosphate, should be used with caution in patients with pancreatic or biliary duct disease because opioids may cause spasm of the sphincter of Oddi and diminish pancreatic and/or biliary secretions.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_178d5225-225d-45b5-8dd1-08a6b51cd06a"></a><a name="section-6.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should be advised to contact their health care provider if they experience any adverse reactions to Carisoprodol, Aspirin and Codeine Phosphate Tablets.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_80052d9a-fb9a-4309-80f9-b32c26df95dc"></a><a name="section-6.2.1"></a><p></p>
<h3>Carisoprodol</h3>
<dl>
<dt>1.</dt>
<dd>Patients should be advised that carisoprodol may cause <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> and/or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and has been associated with <span class="product-label-link" type="condition" conceptid="435134" conceptname="Motor vehicle accident">motor vehicle accidents</span>. Patients should be advised to avoid taking carisoprodol before engaging in potentially hazardous activities such as driving a motor vehicle or operating machinery (see <span class="Bold"><a href="#i4i_warnings_id_e0327034-1ad9-4382-9266-207bd2368459">WARNINGS</a>, <a href="#ID_58b4b38a-fab2-427c-a2f2-925ac6437ef4">Sedation</a></span>).</dd>
<dt>2.</dt>
<dd>Patients should be advised to avoid alcoholic beverages while taking carisoprodol and to check with their doctor before taking other CNS depressants such as benzodiazepines, opioids, tricyclic antidepressants, sedating antihistamines, or other sedatives (see <span class="Bold"><a href="#i4i_warnings_id_e0327034-1ad9-4382-9266-207bd2368459">WARNINGS</a>, <a href="#ID_58b4b38a-fab2-427c-a2f2-925ac6437ef4">Sedation</a></span>).</dd>
<dt>3.</dt>
<dd>Patients should be advised that treatment with carisoprodol should be limited to acute use (up to two or three weeks) for the relief of acute, musculoskeletal <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>. In the post-marketing experience with carisoprodol, cases of <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, withdrawal, and abuse have been reported with prolonged use. If musculoskeletal symptoms still persist, patients should contact their healthcare provider for further evaluation.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e6270378-3df2-4f92-abd5-13e71f86b01d"></a><a name="section-6.2.2"></a><p></p>
<h3><span class="Bold"><span class="Italics">Aspirin</span></span></h3>
<dl>
<dt>1.</dt>
<dd>Patients should be warned that aspirin can cause <span class="product-label-link" type="condition" conceptid="4002232" conceptname="Epigastric discomfort">epigastric discomfort</span>, gastric and <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcers</span>, and serious GI adverse reactions, such as <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, perforation, and/or obstruction of the stomach or intestines, which may result in hospitalization and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Although serious GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> can occur without warning symptoms (e.g., <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">hematochezia</span>), patients should be alert for these symptoms and should seek urgent medical care if any of these indicative symptoms occur (see <span class="Bold"><a href="#i4i_warnings_id_e0327034-1ad9-4382-9266-207bd2368459">WARNINGS</a>, <a href="#i4i_section_id_16ddedab-3460-4edb-a5c2-96e9ceaaf24a">Serious Gastrointestinal Adverse Reactions</a></span>).<span class="Bold"></span>In addition, patients should be alert for symptoms of <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> (e.g., night time <span class="product-label-link" type="condition" conceptid="4002232" conceptname="Epigastric discomfort">epigastric discomfort</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>) and should seek medical attention if these symptoms occur. Patients who consume three or more alcoholic drinks a day should be counseled about the GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> risks involved with the use of aspirin with alcohol.</dd>
<dt>2.</dt>
<dd>Patients should be informed of the symptoms of an <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span> or <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> (e.g., <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>, <span class="product-label-link" type="condition" conceptid="4133326" conceptname="Facial swelling">swelling of face</span> or throat). If these symptoms occur, patients should be instructed to seek immediate emergency help.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_9278871d-9474-40a1-8a22-7222038ee85d"></a><a name="section-6.2.3"></a><p></p>
<h3><span class="Bold"><span class="Italics">Codeine Phosphate</span></span></h3>
<dl>
<dt>1.</dt>
<dd>Since codeine phosphate may cause <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> and/or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, patients should be advised to assess their individual response to codeine phosphate before engaging in potentially hazardous activities such as driving a motor vehicle or operating machinery (see <span class="Bold"><a href="#i4i_warnings_id_e0327034-1ad9-4382-9266-207bd2368459">WARNINGS</a>, <a href="#i4i_section_id_7f8f16b7-a515-4371-8d83-820dadac35e8">Sedation</a></span>).</dd>
<dt>2.</dt>
<dd>Patients should be advised to avoid alcoholic beverages while taking codeine phosphate and to check with their doctor before taking other CNS depressants such as other opioids, benzodiazepines, tricyclic antidepressants, sedating antihistamines, or other sedatives (see <span class="Bold"><a href="#i4i_warnings_id_e0327034-1ad9-4382-9266-207bd2368459">WARNINGS</a>, <a href="#i4i_section_id_7f8f16b7-a515-4371-8d83-820dadac35e8"><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></a></span>and <span class="Bold"><a href="#i4i_section_id_7f8f16b7-a515-4371-8d83-820dadac35e8">Sedation</a></span>).</dd>
<dt>3.</dt>
<dd>Patients should be advised that codeine phosphate is a controlled substance. Codeine phosphate can result in psychological and physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> (see <span class="Bold"><a href="#i4i_warnings_id_e0327034-1ad9-4382-9266-207bd2368459">WARNINGS</a>, <a href="#i4i_section_id_7f8f16b7-a515-4371-8d83-820dadac35e8"><span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span> and Tolerance</a></span>).</dd>
<dt>4.</dt>
<dd>Codeine phosphate tablets should be placed in a secure place out of the reach of children.</dd>
<dt>5.</dt>
<dd>Patients should be advised that opioids, including codeine phosphate, can cause <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> and appropriate measures should be taken to reduce the risk of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> (e.g., dietary changes, laxatives).</dd>
<dt>6.</dt>
<dd>Patients should be advised that opioids, including codeine phosphate, have been associated with <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="4129389" conceptname="Gastrointestinal obstruction">gastrointestinal obstruction</span> <span class="Bold">(<a href="#i4i_warnings_id_e0327034-1ad9-4382-9266-207bd2368459">WARNINGS</a>, <a href="#i4i_section_id_7f8f16b7-a515-4371-8d83-820dadac35e8"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></a>, </span><span class="Bold"><a href="#i4i_section_id_7f8f16b7-a515-4371-8d83-820dadac35e8"><span class="product-label-link" type="condition" conceptid="4129389" conceptname="Gastrointestinal obstruction">Gastrointestinal Obstruction</span></a></span>).</dd>
<dt>7.</dt>
<dd>Advise patients that some people have a genetic variation that results in codeine changing into morphine more rapidly and completely than other people.  Most people are unaware of whether they are an ultra-rapid codeine metabolizer or not.  These higher-than–normal levels of morphine in the blood may lead to life-threatening or fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> or signs of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> such as extreme <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, or <span class="product-label-link" type="condition" conceptid="4302536" conceptname="Shallow breathing">shallow breathing</span>.  Children with this genetic variation who were prescribed codeine after tonsillectomy and/or adenoidectomy for obstructive <span class="product-label-link" type="condition" conceptid="313459" conceptname="Sleep apnea">sleep apnea</span> may be at greatest risk based on reports of several <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> in this population due to <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. As a result, codeine is contraindicated in all children who undergo tonsillectomy and/or adenoidectomy.  Advise caregivers of children receiving codeine for other reasons to monitor for signs of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> (see <span class="Bold"><a href="#i4i_warnings_id_e0327034-1ad9-4382-9266-207bd2368459">WARNINGS</a> – <a href="#i4i_section_id_7f8f16b7-a515-4371-8d83-820dadac35e8"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> Related to Ultra-Rapid Metabolism of Codeine to Morphine</a></span>).</dd>
<dt>8.</dt>
<dd>Nursing mothers using codeine should be informed that a subset of people who use codeine (ultra-rapid metabolizers) may convert codeine into its active metabolite, morphine, resulting in higher than expected exposure of morphine which can lead to toxic serum levels of morphine in infants of nursing mothers. Nursing mothers should be informed how to recognize the symptoms of morphine toxicity in their infants, such as sedation, difficulty breastfeeding, breathing difficulties, and decreased tone (see<span class="Bold"><a href="#i4i_warnings_id_e0327034-1ad9-4382-9266-207bd2368459">WARNINGS</a> - </span><span class="Bold"><a href="#i4i_section_id_7f8f16b7-a515-4371-8d83-820dadac35e8"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> Related to Ultra-Rapid Metabolism of Codeine to Morphine</a></span><span class="Underline">).</span>
</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e35bff3f-c6d9-4f3c-ac60-8fc1bb83faf4"></a><a name="section-6.3"></a><p></p>
<h2>Drug Interactions </h2>
<p class="First"><span class="Bold"><span class="Italics">Carisoprodol</span></span><span class="Bold"><span class="Italics"></span></span></p>
<p>The sedative effect of carisoprodol and other CNS depressants (e.g., alcohol, benzodiazepines, opioids, tricyclic antidepressants) may be additive. Therefore, caution should be exercised with patients who take more than one of these CNS depressants simultaneously. Concomitant use of carisoprodol and meprobamate, a metabolite of carisoprodol, is not recommended (see <span class="Bold"><a href="#i4i_warnings_id_e0327034-1ad9-4382-9266-207bd2368459">WARNINGS</a>, </span><a href="#ID_58b4b38a-fab2-427c-a2f2-925ac6437ef4">Sedation</a><span class="Bold"></span>).</p>
<p>Carisoprodol is metabolized in the liver by CYP2C19 to form meprobamate (see <span class="Bold"><a href="#i4i_clinical_pharmacology_id_f9ac66b6-70f4-4143-895c-20a30b3b5200">CLINICAL PHARMACOLOGY</a></span>).<span class="Bold"></span>Co-administration of CYP2C19 inhibitors, such as omeprazole or fluvoxamine, with carisoprodol could result in increased exposure of carisoprodol and decreased exposure of meprobamate. Co-administration of CYP2C19 inducers, such as rifampin or St. John's Wort, with carisoprodol could result in decreased exposure of carisoprodol and increased exposure of meprobamate. Low dose aspirin also showed an induction effect on CYP2C19. The full pharmacological impact of these potential alterations of exposures in terms of either efficacy or safety of carisoprodol is unknown.</p>
<p><span class="Bold"><span class="Italics">Aspirin </span></span></p>
<p>Clinically important interactions may occur when certain drugs or alcohol are administered concomitantly with aspirin.</p>
<p><span class="Italics">Alcohol: </span>Concomitant use of aspirin with ≥ 3 alcoholic drinks may increase the risk of GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (see <span class="Bold"><a href="#i4i_warnings_id_e0327034-1ad9-4382-9266-207bd2368459">WARNINGS</a>, <a href="#i4i_section_id_16ddedab-3460-4edb-a5c2-96e9ceaaf24a">Serious Gastrointestinal Adverse Reactions</a></span>).</p>
<p><span class="Italics">Anticoagulants: </span>Concomitant use of aspirin and anticoagulants (e.g., heparin, warfarin, clopidogrel) increase the risk of GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (see <span class="Bold"><a href="#i4i_warnings_id_e0327034-1ad9-4382-9266-207bd2368459">WARNINGS</a>, <a href="#i4i_section_id_16ddedab-3460-4edb-a5c2-96e9ceaaf24a">Serious Gastrointestinal Adverse Reactions</a></span>). Additionally, aspirin can displace warfarin from protein binding sites, leading to prolongation of the international normalized ratio (INR).</p>
<p><span class="Italics">Antihypertensives</span><span class="Italics">: </span>The concomitant administration of aspirin with angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta-blockers, and diuretics may diminish the hypotensive effects of these anti-hypertensive products due to aspirin's inhibition of renal prostaglandins, which may lead to decreased renal blood flow and increased sodium and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>. Concomitant use of aspirin and acetazolamide can lead to high serum concentrations of acetazolamide due to competition at the renal tubule for secretion.</p>
<p><span class="Italics">Corticosteroids: </span>Concomitant administration of aspirin and corticosteroids may decrease salicylate plasma levels.</p>
<p><span class="Italics">Methotrexate: </span>Aspirin may enhance the toxicity of methotrexate due to displacement of methotrexate from its plasma protein binding sites and/or reduction of the renal clearance of methotrexate.</p>
<p><span class="Italics">Nonsteroidal</span><span class="Italics"> anti-inflammatory drugs (NSAIDs): </span>The concurrent use of aspirin with selective and nonselective NSAIDs increases the risk of serious GI adverse reactions (see <span class="Bold"><a href="#i4i_warnings_id_e0327034-1ad9-4382-9266-207bd2368459">WARNINGS</a>, <a href="#i4i_section_id_16ddedab-3460-4edb-a5c2-96e9ceaaf24a">Serious Gastrointestinal Adverse Reactions</a></span>).</p>
<p><span class="Italics">Oral </span><span class="Italics">Hypoglycemics</span><span class="Italics"> Agents: </span>Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.</p>
<p><span class="Italics">Products that effect urinary pH: </span>Ammonium chloride and other drugs that acidify the urine can elevate plasma salicylate concentrations. In contrast, antacids, by alkalinizing the urine, may decrease plasma salicylate concentrations.</p>
<p><span class="Italics">Uricosuric</span><span class="Italics"> Agents: </span>Salicylates antagonize the uricosuric action of probenecid and sulfinpyrazone.</p>
<p><span class="Bold"><span class="Italics">Codeine Phosphate </span></span></p>
<p>The sedative effects of codeine phosphate and other CNS depressants (e.g., alcohol, benzodiazepines, other opioids, tricyclic antidepressants) may be additive. Therefore, caution should be exercised with patients who take more than one of these CNS depressants simultaneously (see <span class="Bold"><a href="#i4i_warnings_id_e0327034-1ad9-4382-9266-207bd2368459">WARNINGS</a>, <a href="#i4i_section_id_7f8f16b7-a515-4371-8d83-820dadac35e8"><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></a></span>and<span class="Bold"><a href="#i4i_section_id_7f8f16b7-a515-4371-8d83-820dadac35e8">Sedation</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_70155cb8-0483-4ddc-bb00-c73602996d1c"></a><a name="section-6.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No long-term studies of carcinogenesis have been done with Carisoprodol, Aspirin and Codeine Phosphate Tablets.</p>
<p><span class="Bold"><span class="Italics">Carisoprodol</span></span><span class="Bold"><span class="Italics"></span></span></p>
<p>Long term studies in animals have not been performed to evaluate the carcinogenic potential of carisoprodol.</p>
<p>Carisoprodol was not formally evaluated for genotoxicity. In published studies, carisoprodol was mutagenic in the <span class="Italics">in vitro </span>mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cell assay in the absence of metabolizing enzymes, but was not mutagenic in the presence of metabolizing enzymes. Carisoprodol was clastogenic in the <span class="Italics">in vitro </span>chromosomal aberration assay using Chinese hamster ovary cells with or without the presence of metabolizing enzymes. Other types of genotoxic tests resulted in negative findings. Carisoprodol was not mutagenic in the Ames reverse mutation assay using <span class="Italics">S. </span><span class="Italics">typhimurium</span> <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> with or without metabolizing enzymes, and was not clastogenic in an <span class="Italics">in vitro </span>mouse micronucleus assay of circulating blood cells.</p>
<p>Carisoprodol was not formally evaluated for effects on fertility. Published reproductive studies of carisoprodol in mice found no alteration in fertility although an alteration in reproductive cycles characterized by a greater time spent in estrus was observed at a carisoprodol dose of 1200 mg/kg/day. In a 13-week toxicology study that did not determine fertility, mouse testes weight and sperm motility were reduced at a dose of 1200 mg/kg/day. In both studies, the no effect level was 750 mg/kg/day, corresponding to approximately 2.6 times the human equivalent dosage of 350 mg four times a day, based on a body surface area comparison.</p>
<p>The significance of these findings for human fertility is not known.</p>
<p><span class="Bold"><span class="Italics">Aspirin</span></span></p>
<p>Administration of aspirin for 68 weeks in the feed of rats was not carcinogenic. In the Ames <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> assay, aspirin was not mutagenic; however, aspirin did induce chromosome aberrations in cultured human fibroblasts. Aspirin has been shown to inhibit ovulation in rats (see <span class="Bold"><a href="#i4i_pregnancy_id_d4d428bc-0009-417f-9274-e167faf27d5a">Pregnancy</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_d4d428bc-0009-417f-9274-e167faf27d5a"></a><a name="section-6.5"></a><p></p>
<h2>Pregnancy</h2>
<p class="First"><span class="Bold"><span class="Italics">Pregnancy Category D</span></span></p>
<p>It is not known whether Carisoprodol, Aspirin and Codeine Phosphate Tablets can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Adequate animal reproduction studies have not been conducted with Carisoprodol, Aspirin and Codeine Phosphate Tablets. Carisoprodol, Aspirin and Codeine Phosphate Tablets should be given to a pregnant woman only if clearly needed.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5457931e-aad8-4978-afdb-3385085c3149"></a><a name="section-6.5.1"></a><p></p>
<h3>Carisoprodol </h3>
<p class="First">There are no data on the use of carisoprodol during human pregnancy. Animal studies indicate that carisoprodol crosses the placenta and results in adverse effects on fetal growth and postnatal survival. The primary metabolite of carisoprodol, meprobamate, is an approved anxiolytic. Retrospective, post-marketing studies do not show a consistent association between maternal use of meprobamate and an increased risk for particular congenital malformations.</p>
<p><span class="Italics">Teratogenic</span><span class="Italics"> effects </span></p>
<p>Animal studies have not adequately evaluated the teratogenic effects of carisoprodol. There was no increase in the incidence of congenital malformations noted in the reproductive studies in rats, rabbits, and mice treated with meprobamate. Retrospective, post-marketing studies of meprobamate during human pregnancy were equivocal for demonstrating an increased risk of congenital malformations following the first trimester exposure. Across studies that indicated an increased risk, the types of malformations were inconsistent.</p>
<p><span class="Italics">Nonteratogenic</span><span class="Italics"> effects </span></p>
<p>In animal studies, carisoprodol reduced fetal weights, postnatal <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, and postnatal survival at maternal doses equivalent to 1 to 1.5 times the human dose (based on a body surface area comparison). Rats exposed to meprobamate <span class="Italics">in utero</span> showed behavioral alterations that persisted into adulthood. For children exposed to meprobamate <span class="Italics">in utero</span>, one study found no adverse effects on mental or motor development or IQ scores. Carisoprodol should be used during pregnancy only if the potential benefit justifies the risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ed50beac-6e28-4129-b442-47c370a5114c"></a><a name="section-6.5.2"></a><p></p>
<h3>Aspirin</h3>
<p class="First"><span class="Italics">Teratogenic</span><span class="Italics"> effects </span></p>
<p>Prior to 30 weeks gestation, aspirin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Starting at 30 weeks gestation, aspirin should be avoided by pregnant women as premature closure of the fetal ductus arteriosus which may result in fetal <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span> and <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal death</span>. Salicylate products have also been associated with alterations in maternal and neonatal hemostasis mechanisms, decreased birth weight, increased incidence of <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span> in premature infants, <span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirths</span>, and neonatal <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Studies in rodents have shown salicylates to be teratogenic when given in early gestation, and embryocidal when given in later gestation in doses considerably greater than usual therapeutic doses in humans.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="i4i_labour_delivery_id_f268fecf-56fb-4ffc-ac8d-310ce9cf9177"></a><a name="section-6.6"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First"><span class="Bold"><span class="Italics">Carisoprodol</span></span><span class="Bold"><span class="Italics">:  </span></span>There is no information about the effects of carisoprodol on the mother and the fetus during labor and delivery.</p>
<p><span class="Bold"><span class="Italics">Aspirin:  </span></span>Ingestion of aspirin within one week of delivery or during labor may prolong delivery or lead to excessive blood loss in the mother, fetus, or neonate. <span class="product-label-link" type="condition" conceptid="434714" conceptname="Prolonged second stage of labor">Prolonged labor</span> due to prostaglandin inhibition has been reported with aspirin use.</p>
<p><span class="Bold"><span class="Italics">Codeine Phosphate: </span></span>The use of codeine phosphate during labor may lead to <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in the neonate.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_bad4488a-e24d-4cf8-b3d0-338349a7b066"></a><a name="section-6.7"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First"><span class="Bold"><span class="Italics">Carisoprodol</span></span><span class="Bold"><span class="Italics"></span></span></p>
<p>Very limited data in humans show that carisoprodol is present in breast milk and may reach concentrations two to four times the maternal plasma concentrations. In one case report, a breast-fed infant received about 4 to 6% of the maternal daily dose through breast milk and experienced no adverse effects. However, milk production was inadequate and the baby was supplemented with formula. In lactation studies in mice, female pup survival and pup weight at weaning were decreased. This information suggests that maternal use of carisoprodol may lead to reduced or less effective infant feeding (due to sedation) and/or decreased milk production. Caution should be exercised when carisoprodol is administered to a nursing woman.</p>
<p><span class="Bold"><span class="Italics">Aspirin</span></span></p>
<p>Nursing mothers should avoid the use of aspirin because salicylate is excreted in breast milk which may lead to <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in the infant.</p>
<p><span class="Bold"><span class="Italics">Codeine Phosphate</span></span></p>
<p>Codeine is secreted into human milk. In women with normal codeine metabolism (normal CYP2D6 activity), the amount of codeine secreted into human milk is low. Despite the common use of codeine products to manage postpartum <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, reports of codeine-associated adverse reactions in nursing infants are rare. Nursing mothers who are ultra-rapid metabolizers of codeine have higher-than-expected levels of morphine (the active metabolite of codeine) in their blood, leading to higher levels of morphine in their breast milk and potentially dangerously high serum morphine levels in their breastfed infants. Therefore, in nursing mothers who are ultra-rapid metabolizers of codeine, the maternal use of codeine can lead to serious adverse reactions, including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>; in their nursing infants and in the nursing mothers (see <span class="Bold"><a href="#i4i_warnings_id_e0327034-1ad9-4382-9266-207bd2368459">WARNINGS</a></span> – <span class="Bold"><a href="#i4i_section_id_7f8f16b7-a515-4371-8d83-820dadac35e8"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> Related to Ultra-Rapid Metabolism of Codeine to Morphine</a></span><span class="Bold">).</span></p>
<p>Prior to prescribing nursing mothers codeine phosphate, the risk of infant exposure to codeine and morphine through breast milk should be weighed against the benefits of breastfeeding for both the mother and the infant. If a codeine containing product is selected, the lowest dose should be prescribed for the shortest period of time to achieve the desired clinical effect. Prescribers should closely monitor mother-infant pairs and notify treating pediatricians about the use of codeine during breastfeeding.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_a7171cf7-ede4-4603-8448-8f455c9f2705"></a><a name="section-6.8"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">The efficacy, safety, and pharmacokinetics of Carisoprodol, Aspirin and Codeine Phosphate Tablets in pediatric patients less than 16 years of age have not been established.</p>
<p><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have occurred in children with obstructive <span class="product-label-link" type="condition" conceptid="313459" conceptname="Sleep apnea">sleep apnea</span> who received codeine in the post-operative period following tonsillectomy and/or adenoidectomy and had evidence of being ultra-rapid metabolizers of codeine (i.e., multiple copies of the gene for CYP2D6 or high morphine concentrations).  These children may be particularly sensitive to the respiratory depressant effects of codeine that has been rapidly metabolized to morphine.  Codeine is contraindicated for post-operative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> management in these patients (see <span class="Bold"><a href="#i4i_warnings_id_e0327034-1ad9-4382-9266-207bd2368459">WARNINGS</a> – <a href="#i4i_section_id_7f8f16b7-a515-4371-8d83-820dadac35e8"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> Related to Ultra-Rapid Metabolism of Codeine to Morphine</a></span>and<span class="Bold"></span><span class="Bold"><a href="#i4i_contraindications_id_00b7e679-a17f-4e20-82f9-fe14d1091a97">CONTRAINDICATIONS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID_fb850b83-6ee8-48cb-9aac-0189c591cf4a"></a><a name="section-6.9"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">The efficacy, safety, and pharmacokinetics of Carisoprodol, Aspirin and Codeine Phosphate Tablets in geriatric patients over 65 years of age have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_1b14c96b-6bd0-4afa-a663-84456bdbdc2d"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or <a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a>.</span></p>
<p>The following adverse reactions which have occurred with the administration of the individual products alone may also occur with the use of Carisoprodol, Aspirin and Codeine Phosphate Tablets. The following events have been reported during post-approval individual use of carisoprodol, aspirin, and codeine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="Bold"><span class="Italics">Carisoprodol</span></span></p>
<p><span class="Italics">Cardiovascular: </span><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>, and <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">facial flushing</span> (see <span class="Bold"><a href="#i4i_overdosage_id_f4be16ec-411d-4db0-baf0-1ff24888d9b9">OVERDOSAGE</a></span>).</p>
<p><span class="Italics">Central Nervous System: </span><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, depressive reactions, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> (see <span class="Bold"><a href="#i4i_overdosage_id_f4be16ec-411d-4db0-baf0-1ff24888d9b9">OVERDOSAGE</a></span>).</p>
<p><span class="Italics">Gastrointestinal: </span><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="4002232" conceptname="Epigastric discomfort">epigastric discomfort</span>. </p>
<p><span class="Italics">Hematologic: </span><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>.</p>
<p><span class="Bold"><span class="Italics">Aspirin</span></span></p>
<p>The most common adverse reactions associated with the use of aspirin have been gastrointestinal, including both <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, and occult <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (see <span class="Bold"><a href="#i4i_warnings_id_e0327034-1ad9-4382-9266-207bd2368459">WARNINGS</a>, </span><span class="Bold"><a href="#i4i_section_id_16ddedab-3460-4edb-a5c2-96e9ceaaf24a">Serious Gastrointestinal Adverse Reactions</a></span><span class="Bold"></span>and <span class="Bold"><a href="#i4i_precautions_id_4e64cc3d-ad51-4846-a3c9-7cf3a20347fb">PRECAUTIONS</a>, </span><span class="Bold"><a href="#i4i_section_id_5e5b27d7-06a8-4252-b971-02aeb8435eb4">Gastrointestinal Adverse Reactions</a></span>).<span class="Bold"></span>Other adverse reactions associated with the use of aspirin include elevated liver enzymes, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span>, interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, and <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>. <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">Tinnitus</span> may be a sign of high serum salicylate levels (see <span class="Bold"><a href="#i4i_overdosage_id_f4be16ec-411d-4db0-baf0-1ff24888d9b9">OVERDOSAGE</a></span>).</p>
<p><span class="Bold"><span class="Italics">Codeine Phosphate </span></span></p>
<p><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>, sedation, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>.</p>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="i4i_abuse_dependence_id_ba20f581-ba78-4354-8ba1-6db7390d3e66"></a><a name="section-8"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<div class="Section" data-sectionCode="34085-1">
<a name="i4i_controlled_substance_id_1bc8e303-a1d1-404e-aa1d-9bdd100ad44d"></a><a name="section-8.1"></a><p></p>
<h2>Controlled Substance: </h2>
<p class="First">Schedule C-III (see <span class="Bold"><a href="#i4i_warnings_id_e0327034-1ad9-4382-9266-207bd2368459">WARNINGS</a></span>).</p>
<p><span class="Bold">Controlled Substance</span></p>
<p>Carisoprodol is a Schedule IV controlled substance.  Carisoprodol has been subject to abuse, misuse, and criminal diversion for nontherapeutic use (see <span class="Bold"><a href="#i4i_warnings_id_e0327034-1ad9-4382-9266-207bd2368459">WARNINGS</a></span>). </p>
<p><span class="Bold">Abuse </span></p>
<p>Abuse of carisoprodol poses a risk of overdosage which may lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, CNS and <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> and other disorders (see <span class="Bold"><a href="#i4i_warnings_id_e0327034-1ad9-4382-9266-207bd2368459">WARNINGS</a></span>). Patients at high risk of carisoprodol abuse may include those with prolonged use of carisoprodol, with a history of drug abuse, or those who use carisoprodol in combination with other abused drugs. </p>
<p>Prescription drug abuse is the intentional non-therapeutic use of a drug, even once, for its rewarding psychological or physiological effects. <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug addiction</span>, which develops after repeated drug abuse, is characterized by a strong desire to take a drug despite harmful consequences, difficulty in controlling its use, giving a higher priority to drug use than to obligations, increased tolerance, and sometimes physical withdrawal.  Drug abuse and <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug addiction</span> are separate and distinct from physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and tolerance (for example, abuse or addiction may not be accompanied by tolerance or physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>) (see <span class="Bold"><a href="#i4i_controlled_substance_id_1bc8e303-a1d1-404e-aa1d-9bdd100ad44d"><span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></a></span>). </p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span> </span></p>
<p>Tolerance is when a patient’s reaction to a specific dosage and concentration is progressively reduced, in the absence of disease progression, requiring an increase in the dosage to maintain the same. Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> is characterized by withdrawal symptoms after abrupt discontinuation or a significant dose reduction of a drug.  Both tolerance and physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> have been reported with prolonged use of carisoprodol.  Reported withdrawal symptoms with carisoprodol include <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">muscle twitching</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, and <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>.  Instruct patients taking large doses of carisoprodol or those taking the drug for a prolonged time to not abruptly stop carisoprodol (see <span class="Bold"><a href="#i4i_warnings_id_e0327034-1ad9-4382-9266-207bd2368459">WARNINGS</a></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_f4be16ec-411d-4db0-baf0-1ff24888d9b9"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First"><span class="Bold">Signs and Symptoms: </span>Any of the following signs and symptoms which have been reported with <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of the individual products may occur with <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of Carisoprodol, Aspirin and Codeine Phosphate Tablets and may be modified to a varying degree by the effects of the other products present in Carisoprodol, Aspirin and Codeine Phosphate Tablets.</p>
<p><span class="Bold"><span class="Italics">Carisoprodol</span></span><span class="Bold"><span class="Italics">:  </span></span>Overdosage of carisoprodol commonly produces <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonic reactions</span>, <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">nystagmus</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">muscular incoordination</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span>, and/or <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> have been reported with carisoprodol overdosage. <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> has been reported with carisoprodol <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>. Many of the carisoprodol <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> have occurred in the setting of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">multiple drug overdoses</span> (including drugs of abuse, illegal drugs, and alcohol). The effects of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of carisoprodol and other CNS depressants (e.g., alcohol, benzodiazepines, opioids, tricyclic antidepressants) can be additive even when one of the drugs has been taken in the recommended dosage. Fatal accidental and non-accidental <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> of carisoprodol have been reported alone or in combination with CNS depressants.</p>
<p><span class="Bold"><span class="Italics">Aspirin:  </span></span>Salicylate toxicity may result from an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of an acute ingestion or chronic <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>. Mild to moderate salicylate <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> is usually associated with plasma salicylic concentrations about 200 mcg/mL and is characterized by <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, hearing difficulty, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, dim vision, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">tachypnea</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">increased thirst</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. In the early stages of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, CNS stimulation and <span class="product-label-link" type="condition" conceptid="4006309" conceptname="Respiratory alkalosis">respiratory alkalosis</span> can occur; however, in the later stages <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span> and <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> can occur.</p>
<p>Symptoms and signs of severe salicylate <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>, associated with plasma salicylic concentrations greater than 400 mcg/mL, include <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">GI hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, and <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span> (e.g., <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>). <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> is usually due to <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span> or <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span> of aspirin in pediatric patients:  </span>Salicylate <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> should be considered in pediatric patients with symptoms of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperpnea</span>, and <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>. Salicylate <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> should be considered in infants with <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> and all pediatric patients with severe salicylate <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>.</p>
<p><span class="Italics"><span class="Bold">Codeine Phosphat</span>e:  </span><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Acute overdose</span> of opioids, including codeine phosphate, is characterized by <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span> (<span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> progressing to <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>), <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>, skeletal muscle <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">flaccidity</span>, and <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> and <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">clammy</span> skin.</p>
<p><span class="Bold">Treatment of </span><span class="Bold">Overdosage</span><span class="Bold">: </span>Provide symptomatic and supportive treatment, as indicated. For more information on the management of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of Carisoprodol, Aspirin and Codeine Phosphate Tablets, <span class="Bold">contact a Poison Control Center.</span></p>
<p><span class="Bold"><span class="Italics">Carisoprodol</span></span><span class="Bold"><span class="Italics">:  </span></span>Basic life support measures should be instituted as dictated by the clinical presentation of the carisoprodol <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> should not be induced due to the risk of CNS and <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, and subsequent <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span>. Gastric lavage should be considered soon after ingestion (within one hour). Circulatory support should be administered with volume infusion and vasopressor agents if needed. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> should be treated with intravenous benzodiazepines and the reoccurrence of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> may be treated with phenobarbital. In cases of severe <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>, airway protective reflexes may be compromised and tracheal intubation should be considered for airway protection and respiratory support. For decontamination in cases of severe toxicity, activated charcoal should be considered in a hospital setting in patients with large <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> who present early and are not demonstrating <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span> and can protect their airway.</p>
<p><span class="Bold"><span class="Italics">Aspirin:  </span></span>Since there are no specific antidotes for salicylate <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>, the aim of the treatment is to enhance elimination of salicylate; reduce further salicylate absorption; correct fluid, electrolyte, or acid/base imbalances; and provide cardio-respiratory support. The acid-base status should be followed closely with serial serum pH determinations (using arterial blood gas). If <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span> is present, intravenous sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> should be given, along with adequate hydration, until salicylate levels decrease to within the therapeutic range. To enhance elimination, forced <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> and alkalinization of the urine may be beneficial. Gastric emptying and/or lavage are recommended as soon as possible after ingestion, even if the patient has <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomited</span> spontaneously. After lavage and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>, administration of activated charcoal is beneficial, if less than 3 hours have passed since ingestion. Charcoal absorption should not be employed prior to <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> and lavage. In patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> or in cases of life-threatening aspirin <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>, hemodialysis or peritoneal dialysis is usually required.</p>
<p><span class="Italics">Additional treatment of aspirin <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> in pediatric patients: </span>Pediatric patients should be sponged with tepid water. Infusion of glucose may be required to control <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. Exchange transfusion may be indicated in infants and young children.</p>
<p><span class="Bold"><span class="Italics">Codeine Phosphate:  </span></span>After a severe opioid <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, primary attention should be given to the need for re-establishment of a patent airway and institution of assisted ventilation. Elimination or evacuation of gastric contents may be necessary in order to eliminate unabsorbed drug. Before attempting treatment by gastric emptying or activated charcoal, care should be taken to secure the airway. Pure opioid antagonist (e.g., naloxone, nalmefene) are specific antidotes to severe respiratory and <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span> resulting from opioid <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. If the response to these opioid antagonists is sub-optimal, additional antagonist should be administered. Since the duration of action of codeine may exceed that of the opioid antagonist, the patient's respiratory status should be continuously monitored for the need for additional doses of antagonist to maintain adequate respiration.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_f4c8befc-3509-4f13-9561-de990cf84bcb"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The recommended daily dose of Carisoprodol, Aspirin and Codeine Phosphate Tablets, USP is 1 or 2 tablets, four times daily in adults. One Carisoprodol, Aspirin and Codeine Phosphate Tablet, USP contains 200 mg of carisoprodol, 325 mg of aspirin, and 16 mg of codeine phosphate. The maximum daily dose (i.e., two tablets taken four times daily) will provide 1600 mg of carisoprodol, 2600 mg of aspirin, and 128 mg of codeine phosphate per day. The recommended maximum duration of Carisoprodol, Aspirin and Codeine Phosphate Tablet, USP use is up to two or three weeks.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_f2d5e603-73b1-4bf5-a429-a0dad95d7000"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Carisoprodol, Aspirin and Codeine Phosphate Tablets, USP are supplied as: </p>
<p>Carisoprodol 200 mg, Aspirin 325 mg and Codeine Phosphate 16 mg, round, two-layered yellow and white tablets; imprinted "<span class="Italics">E</span>749" and are available in bottles of 100, 500, and 1000.</p>
<p>NDC 0185-0749-01, bottles of 100 tablets</p>
<p>NDC 0185-0749-05, bottles of 500 tablets</p>
<p>NDC 0185-0749-10, bottles of 1000 tablets</p>
<p><span class="Bold">Storage</span></p>
<p>Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Protect from moisture.  Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).</p>
<p>Manufactured for</p>
<p>Sandoz Inc. </p>
<p>Princeton, NJ 08540</p>
<p>Manufactured by</p>
<p>Epic Pharma, LLC</p>
<p>Laurelton, NY 11413</p>
<p>OS7183</p>
<p>Rev. May 2013</p>
<p>MF0749REV05/13</p>
<p>MG #11322</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_f494a47b-a670-458d-add7-77f9043600f6"></a><a name="section-12"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><span class="Bold">NDC</span> 0185-0749-01</p>
<p><span class="Bold">Carisoprodol</span><span class="Bold">, Aspirin and Codeine Phosphate Tablets, USP CIII</span></p>
<p><span class="Bold">200 mg/325 mg/16 mg</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">100 Tablets</span></p>
<p><span class="Bold">SANDOZ</span></p>
<div class="Figure">
<a name="id893"></a><img alt="100s label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dcae7a8a-9d9e-4f7f-954c-39e371f30f75&amp;name=a6b304e5-073f-48b6-9f17-ddfa94ecf2db-04.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE 		
					</strong><br><span class="contentTableReg">carisoprodol, aspirin and codeine phosphate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0185-0749</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CARISOPRODOL</strong> (CARISOPRODOL) </td>
<td class="formItem">CARISOPRODOL</td>
<td class="formItem">200 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>ASPIRIN</strong> (ASPIRIN) </td>
<td class="formItem">ASPIRIN</td>
<td class="formItem">325 mg</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CODEINE PHOSPHATE</strong> (CODEINE ANHYDROUS) </td>
<td class="formItem">CODEINE PHOSPHATE</td>
<td class="formItem">16 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW, WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">E;749</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0185-0749-10</td>
<td class="formItem">1000  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0185-0749-05</td>
<td class="formItem">500  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0185-0749-01</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040118</td>
<td class="formItem">04/16/1996</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Eon Labs, Inc.
							(012656273)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 5/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>a6b304e5-073f-48b6-9f17-ddfa94ecf2db</div>
<div>Set id: dcae7a8a-9d9e-4f7f-954c-39e371f30f75</div>
<div>Version: 4</div>
<div>Effective Time: 20130520</div>
</div>
</div> <div class="DistributorName">Eon Labs, Inc.</div></p>
</body></html>
